KR20230152800A - 주요 부정적 심혈관 사건을 감소시키기 위한 조성물 및 방법 - Google Patents

주요 부정적 심혈관 사건을 감소시키기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20230152800A
KR20230152800A KR1020237036479A KR20237036479A KR20230152800A KR 20230152800 A KR20230152800 A KR 20230152800A KR 1020237036479 A KR1020237036479 A KR 1020237036479A KR 20237036479 A KR20237036479 A KR 20237036479A KR 20230152800 A KR20230152800 A KR 20230152800A
Authority
KR
South Korea
Prior art keywords
naltrexone
bupropion
subject
pharmaceutical composition
fatal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237036479A
Other languages
English (en)
Korean (ko)
Inventor
프레스톤 클라센
크리스틴 테일러
Original Assignee
오렉시젠 세러퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52575014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20230152800(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 오렉시젠 세러퓨틱스 인크. filed Critical 오렉시젠 세러퓨틱스 인크.
Publication of KR20230152800A publication Critical patent/KR20230152800A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020237036479A 2013-12-06 2014-12-04 주요 부정적 심혈관 사건을 감소시키기 위한 조성물 및 방법 Pending KR20230152800A (ko)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201361913216P 2013-12-06 2013-12-06
US61/913,216 2013-12-06
US201361914938P 2013-12-11 2013-12-11
US61/914,938 2013-12-11
US201461984580P 2014-04-25 2014-04-25
US61/984,580 2014-04-25
US14/322,810 2014-07-02
US14/322,810 US8969371B1 (en) 2013-12-06 2014-07-02 Compositions and methods for weight loss in at risk patient populations
KR1020227041333A KR20220165791A (ko) 2013-12-06 2014-12-04 주요 부정적 심혈관 사건을 감소시키기 위한 조성물 및 방법
PCT/US2014/068527 WO2015085044A1 (en) 2013-12-06 2014-12-04 Compositions and methods for reducing major adverse cardiovascular events

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227041333A Division KR20220165791A (ko) 2013-12-06 2014-12-04 주요 부정적 심혈관 사건을 감소시키기 위한 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20230152800A true KR20230152800A (ko) 2023-11-03

Family

ID=52575014

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020167017977A Active KR102472432B1 (ko) 2013-12-06 2014-12-04 주요 부정적 심혈관 사건을 감소시키기 위한 조성물 및 방법
KR1020227041333A Ceased KR20220165791A (ko) 2013-12-06 2014-12-04 주요 부정적 심혈관 사건을 감소시키기 위한 조성물 및 방법
KR1020237036479A Pending KR20230152800A (ko) 2013-12-06 2014-12-04 주요 부정적 심혈관 사건을 감소시키기 위한 조성물 및 방법

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020167017977A Active KR102472432B1 (ko) 2013-12-06 2014-12-04 주요 부정적 심혈관 사건을 감소시키기 위한 조성물 및 방법
KR1020227041333A Ceased KR20220165791A (ko) 2013-12-06 2014-12-04 주요 부정적 심혈관 사건을 감소시키기 위한 조성물 및 방법

Country Status (33)

Country Link
US (9) US8969371B1 (enExample)
EP (2) EP4005571A1 (enExample)
JP (2) JP6665094B2 (enExample)
KR (3) KR102472432B1 (enExample)
CN (3) CN105899210A (enExample)
AU (1) AU2014360492A1 (enExample)
BR (1) BR112016012755A2 (enExample)
CA (1) CA2932127C (enExample)
CL (1) CL2016001362A1 (enExample)
CR (1) CR20160313A (enExample)
CY (1) CY1125114T1 (enExample)
DK (1) DK3076971T3 (enExample)
EA (1) EA201690964A1 (enExample)
EC (1) ECSP16057765A (enExample)
ES (1) ES2903391T3 (enExample)
HR (1) HRP20220058T1 (enExample)
HU (1) HUE057551T2 (enExample)
IL (3) IL300870A (enExample)
JO (1) JOP20140344B1 (enExample)
LT (1) LT3076971T (enExample)
MX (2) MX389742B (enExample)
PE (1) PE20161034A1 (enExample)
PL (1) PL3076971T3 (enExample)
PT (1) PT3076971T (enExample)
RS (1) RS62846B1 (enExample)
RU (1) RU2711638C2 (enExample)
SG (1) SG10201808055QA (enExample)
SI (1) SI3076971T1 (enExample)
TN (1) TN2016000231A1 (enExample)
TW (1) TWI661826B (enExample)
UY (1) UY35864A (enExample)
WO (1) WO2015085044A1 (enExample)
ZA (1) ZA201603831B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004012403T2 (de) 2003-04-29 2009-03-19 Orexigen Therapeutics, Inc., La Jolla Zusammensetzungen zur beeinflussung des gewichtsverlusts
PL2135603T3 (pl) 2005-11-22 2013-09-30 Orexigen Therapeutics Inc Kompozycje i sposoby zwiększania wrażliwości na insulinę
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
TW200829235A (en) 2006-11-09 2008-07-16 Orexigen Therapeutics Inc Methods for administering weight loss medications
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
CA2875056C (en) * 2012-06-06 2024-03-26 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
BR112019002781A2 (pt) * 2016-08-11 2019-07-09 Huawei Tech Co Ltd método de comunicação sem fio, estação base e dispositivo terminal baseado em espectro não licenciado
EP4444417A1 (en) * 2021-12-09 2024-10-16 InCarda Therapeutics, Inc. Inhaled therapy for cardiac arrhythmia
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217353A (en) 1978-05-19 1980-08-12 E. I. Du Pont De Nemours And Company Method for inducing anorexia
IL58649A (en) 1978-11-10 1982-04-30 Beecham Group Ltd Pharmaceutical dispensing container
WO1983003197A1 (en) 1982-03-16 1983-09-29 Univ Rockefeller Method for controlling gastrointestinal dysmotility
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
ES2058272T3 (es) 1987-05-04 1994-11-01 Lilly Co Eli Fluoxetina util para el tratamiento de la diabetes.
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US5403595A (en) 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
DE4136215A1 (de) 1991-11-02 1993-05-06 Ferring Arzneimittel Gmbh, 2300 Kiel, De Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
AU3419995A (en) 1994-09-19 1996-04-09 Du Pont Merck Pharmaceutical Company, The Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US5627187A (en) 1995-04-12 1997-05-06 Katz; Bruce E. 5-FU for treating actinic kerotoses
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
EP0828489A4 (en) 1996-03-13 2001-04-04 Univ Yale Smoking cessation treatments using naltrexone and related compounds
US5716976A (en) 1996-03-13 1998-02-10 Bernstein; Richard K. Method of treatment for carbohydrate addiction
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
DK0934069T3 (da) 1996-05-07 2007-03-19 Pliva Istrazivanje I Razvoj D Fremgangsmåde og apparat til behandling af lipid- og glucosemetabolismelidelser
WO1998000130A2 (en) 1996-06-28 1998-01-08 Ortho Pharmaceutical Corporation Anticonvulsant sulfamate derivatives useful in treating obesity
US5878750A (en) 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
DE69811378T2 (de) 1997-10-03 2004-02-12 Cary Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) Zusammensetzungen zur behandlung von nikotinabhängigkeit, enthaltend mecamylamin und bupropion
US6262049B1 (en) 1997-10-28 2001-07-17 Schering Corporation Method of reducing nicotine and tobacco craving in mammals
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US6048322A (en) 1998-04-15 2000-04-11 Kushida; Clete Morphometric measurement tool
US6589553B2 (en) 2001-02-08 2003-07-08 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
US6210716B1 (en) 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
US6071918A (en) 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
WO2001019321A2 (en) 1999-09-15 2001-03-22 Elan Pharmaceuticals, Inc. Methods for treating neuropathic pain using hetreoarylmethanesulfonamides
US6403657B1 (en) 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
AR031682A1 (es) 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
GB0001449D0 (en) 2000-01-21 2000-03-08 Cortendo Ab Compositions
US20020055512A1 (en) 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
KR20020081271A (ko) 2000-01-22 2002-10-26 알버트 슐만 물질 남용의 치료 방법
WO2001052851A1 (en) 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
WO2001058447A1 (en) 2000-02-08 2001-08-16 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
US6306436B1 (en) 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
EP1326630B1 (en) 2000-09-18 2008-05-28 Sanos Bioscience A/S Use of glp-2 peptides
EP1392250A2 (en) 2001-06-08 2004-03-03 Endo Pharmaceuticals Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
ES2326794T3 (es) 2001-08-06 2009-10-20 Euro-Celtique S.A. Formulaciones de agonistas opioides con antagonista liberable y secuestrado.
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
BR0212019A (pt) 2001-08-06 2005-08-09 Euro Celtique Sa Formas de dosagem, métodos para o tratamento da dor, métodos de preparação de uma forma de dosagem e métodos para impedir o abuso de uma forma de dosagem
US20030087896A1 (en) 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US20040102440A1 (en) 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
US20040029941A1 (en) 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
EP1505974B1 (en) 2002-05-17 2009-04-22 Tioga Pharmaceuticals, Inc. Use of compounds that are effective as selective opiate receptor modulators
WO2003097046A1 (en) 2002-05-17 2003-11-27 Duke University Method for treating obesity
US20040005368A1 (en) 2002-07-01 2004-01-08 Morris Mann Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite
US6972291B2 (en) 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
US7086532B2 (en) 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
AU2003283958A1 (en) 2002-09-13 2004-04-30 Elan Pharmaceuticals, Inc. Method of treating tremors
US20040192715A1 (en) 2003-02-05 2004-09-30 Mark Chasin Methods of administering opioid antagonists and compositions thereof
WO2004078113A2 (en) 2003-03-04 2004-09-16 Pharmacia Corporation Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
EP1613324A2 (en) 2003-04-14 2006-01-11 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
DE602004012403T2 (de) 2003-04-29 2009-03-19 Orexigen Therapeutics, Inc., La Jolla Zusammensetzungen zur beeinflussung des gewichtsverlusts
EP1633400A2 (en) 2003-05-16 2006-03-15 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
WO2004110375A2 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of diabetes
JP4758897B2 (ja) 2003-09-25 2011-08-31 ユーロ−セルティーク エス．エイ． ヒドロコドンとナルトレキソンとの併用医薬
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US20070149451A1 (en) 2003-11-17 2007-06-28 Holmes David G Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
BRPI0506829A (pt) 2004-01-13 2007-05-29 Univ Duke composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
US20050245541A1 (en) 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
US20050277579A1 (en) 2004-05-03 2005-12-15 Ranga Krishnan Compositions for affecting weight loss
US20050250838A1 (en) 2004-05-04 2005-11-10 Challapalli Prasad V Formulation for sustained delivery
KR20070083534A (ko) 2004-08-03 2007-08-24 오렉시젠 세러퓨틱스 인크. 체중감량을 위한 부프로피온과 제2화합물의 조합
WO2007047351A2 (en) 2005-10-13 2007-04-26 Orexigen Therapeutics, Inc. Methods for treating hypertension in overweight and obese individuals
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
PL2135603T3 (pl) 2005-11-22 2013-09-30 Orexigen Therapeutics Inc Kompozycje i sposoby zwiększania wrażliwości na insulinę
WO2007089318A2 (en) 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
WO2007064586A1 (en) 2005-11-28 2007-06-07 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
EP1813276A1 (en) 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
EP2061448B1 (en) 2006-06-05 2019-07-17 Nalpropion Pharmaceuticals, Inc. Sustained release formulation of naltrexone
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
PT2484346T (pt) 2006-06-19 2017-04-26 Alpharma Pharmaceuticals Llc Composições farmacêuticas
CA2693992C (en) 2006-07-20 2017-01-31 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US8682445B2 (en) 2006-07-28 2014-03-25 Cyberonics, Inc. Patient management system for treating depression using an implantable medical device
TW200829235A (en) 2006-11-09 2008-07-16 Orexigen Therapeutics Inc Methods for administering weight loss medications
EP2089005B1 (en) * 2006-11-09 2010-03-17 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
GB2447949B (en) 2007-03-29 2010-03-31 Renasci Consultancy Ltd A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
JP6196041B2 (ja) * 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
TW201735912A (zh) 2010-12-03 2017-10-16 歐瑞根治療有限公司 降低暴食或強迫進食之方法
CA2875056C (en) * 2012-06-06 2024-03-26 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Also Published As

Publication number Publication date
TW201607536A (zh) 2016-03-01
US10828294B2 (en) 2020-11-10
RS62846B1 (sr) 2022-02-28
SG10201808055QA (en) 2018-10-30
AU2014360492A1 (en) 2016-06-23
CY1125114T1 (el) 2023-06-09
CN105899210A (zh) 2016-08-24
MX389742B (es) 2025-03-20
JP2020037593A (ja) 2020-03-12
US20150366860A1 (en) 2015-12-24
IL245919A0 (en) 2016-07-31
MX2022001251A (es) 2022-02-23
IL300870A (en) 2023-04-01
US9801875B2 (en) 2017-10-31
US8969371B1 (en) 2015-03-03
ZA201603831B (en) 2023-05-31
US20190374535A1 (en) 2019-12-12
RU2711638C2 (ru) 2020-01-17
CN114404419A (zh) 2022-04-29
KR20220165791A (ko) 2022-12-15
PL3076971T3 (pl) 2022-04-04
US10231962B2 (en) 2019-03-19
ECSP16057765A (es) 2017-02-24
US10835527B2 (en) 2020-11-17
US10231964B2 (en) 2019-03-19
US20250144089A1 (en) 2025-05-08
EP3076971A4 (en) 2017-06-28
EP3076971A1 (en) 2016-10-12
CL2016001362A1 (es) 2017-01-06
KR102472432B1 (ko) 2022-11-30
BR112016012755A2 (pt) 2017-08-08
KR20160095076A (ko) 2016-08-10
JP6665094B2 (ja) 2020-03-13
EP4005571A1 (en) 2022-06-01
WO2015085044A1 (en) 2015-06-11
US20210069181A1 (en) 2021-03-11
TWI661826B (zh) 2019-06-11
EP3076971B1 (en) 2021-10-20
IL282117A (en) 2021-05-31
ES2903391T3 (es) 2022-04-01
NZ720620A (en) 2022-03-25
JP7204634B2 (ja) 2023-01-16
PT3076971T (pt) 2022-01-26
US20190314363A1 (en) 2019-10-17
CA2932127C (en) 2023-05-02
MX2016007231A (es) 2016-08-04
TN2016000231A1 (en) 2017-10-06
CA2932127A1 (en) 2015-06-11
JOP20140344B1 (ar) 2021-08-17
JP2016539164A (ja) 2016-12-15
LT3076971T (lt) 2022-02-10
US9119850B2 (en) 2015-09-01
US20180243288A1 (en) 2018-08-30
PE20161034A1 (es) 2016-11-13
EA201690964A1 (ru) 2016-12-30
US20160310485A1 (en) 2016-10-27
US11998542B2 (en) 2024-06-04
UY35864A (es) 2015-07-31
DK3076971T3 (da) 2022-01-24
US20150182524A1 (en) 2015-07-02
HRP20220058T1 (hr) 2022-04-15
CN117159547A (zh) 2023-12-05
HUE057551T2 (hu) 2022-05-28
CR20160313A (es) 2018-01-26
SI3076971T1 (sl) 2022-04-29

Similar Documents

Publication Publication Date Title
US20250144089A1 (en) Compositions And Methods For Reducing Major Adverse Cardiovascular Events
EP2858640B1 (en) Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
NZ720620B2 (en) Compositions and methods for reducing major adverse cardiovascular events
RU2788450C2 (ru) Способы проведения терапии потери веса у пациентов с доминирующей депрессией
TW201208676A (en) Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular hospitalization or of mortality in patients with lone atrial fibrillation

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000